Leonny Dwi Rizkita, Indwiani Astuti. Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271][J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 937-937. doi: 10.1016/j.jpha.2022.11.001
| Citation:
|
Leonny Dwi Rizkita, Indwiani Astuti. Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271][J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 937-937. doi: 10.1016/j.jpha.2022.11.001
|
Leonny Dwi Rizkita, Indwiani Astuti. Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271][J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 937-937. doi: 10.1016/j.jpha.2022.11.001
| Citation:
|
Leonny Dwi Rizkita, Indwiani Astuti. Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271][J]. Journal of Pharmaceutical Analysis, 2022, 12(6): 937-937. doi: 10.1016/j.jpha.2022.11.001
|
Corrigendum to “The potential of miRNA-based therapeutics in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A review” [J. Pharma. Anal. 11 (2021) 265–271]
-
Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
- Publish Date:
Dec. 26, 2022
DownLoad: